These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34696438)

  • 41. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
    Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication.
    Ogawa E; Toyoda H; Iio E; Jun DW; Huang CF; Enomoto M; Hsu YC; Haga H; Iwane S; Wong G; Lee DH; Tada T; Liu CH; Chuang WL; Hayashi J; Cheung R; Yasuda S; Tseng CH; Takahashi H; Tran S; Yeo YH; Henry L; Barnett SD; Nomura H; Nakamuta M; Dai CY; Huang JF; Yang HI; Lee MH; Jun MJ; Kao JH; Eguchi Y; Ueno Y; Tamori A; Furusyo N; Yu ML; Tanaka Y; Nguyen MH;
    Clin Infect Dis; 2020 Dec; 71(11):2840-2848. PubMed ID: 31777940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
    Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
    EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    D'Ambrosio R; Degasperi E; Anolli MP; Fanetti I; Borghi M; Soffredini R; Iavarone M; Tosetti G; Perbellini R; Sangiovanni A; Sypsa V; Lampertico P
    J Hepatol; 2022 Feb; 76(2):302-310. PubMed ID: 34592366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
    Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
    [No Abstract]   [Full Text] [Related]  

  • 46. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic Performance of microRNA-122 and microRNA-224 in Hepatitis C Virus-Induced Hepatocellular Carcinoma (HCC).
    Shehab-Eldeen S; Nada A; Abou-Elela D; El-Naidany S; Arafat E; Omar T
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2515-2522. PubMed ID: 31450927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of
    Antwi SO; Van Houten HK; Sangaralingham LR; Patel T
    Cancer Prev Res (Phila); 2019 Dec; 12(12):891-902. PubMed ID: 31451519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful.
    Abdelhamed W; El-Kassas M
    J Viral Hepat; 2023 Feb; 30(2):148-159. PubMed ID: 36461645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study.
    Choi GH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Jang JW; Ki M; Choi HY; Baik D; Jeong SH
    World J Gastroenterol; 2022 Aug; 28(30):4182-4200. PubMed ID: 36157119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
    Kawagishi N; Suda G; Yamamoto Y; Baba M; Furuya K; Maehara O; Ohnishi S; Yoshida S; Fu Q; Yang Z; Hosoda S; Tokuchi Y; Kitagataya T; Ohara M; Suzuki K; Nakai M; Sho T; Natsuizaka M; Ogawa K; Sakamoto N
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study.
    Hyun HK; Cho EJ; Park SY; Hong YM; Kim SS; Kim HY; Heo NY; Park JG; Sinn DH; Kang W; Jeong SW; Song MJ; Park H; Lee D; Lee YS; Cho SB; An CS; Rhee HJ; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee JH; Yu SJ; Kim YJ; Yoon JH; Tak WY; Kweon YO; Yoon KT; Cho M; Cheong JY; Park SH; Kim SU;
    Dig Dis Sci; 2021 Jul; 66(7):2427-2438. PubMed ID: 32856240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
    Chen CY; Huang CF; Cheng PN; Tseng KC; Lo CC; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Kao JH; Chuang WL; Lin HC; Yu ML
    Liver Int; 2021 Jun; 41(6):1265-1277. PubMed ID: 33655714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data.
    Yen YH; Chen CH; Hung CH; Wang JH; Lu SN; Kee KM; Hu TH
    PLoS One; 2019; 14(10):e0222605. PubMed ID: 31581209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.
    Wirth TC; Manns MP
    Ann Oncol; 2016 Aug; 27(8):1467-74. PubMed ID: 27226385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C.
    Takemura K; Takizawa E; Tamori A; Nakamae M; Kubota H; Uchida-Kobayashi S; Enomoto M; Kawada N; Hino M
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
    Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
    J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
    J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma.
    Rashad NM; El-Shal AS; Shalaby SM; Mohamed SY
    Mol Cell Biochem; 2018 Oct; 447(1-2):125-136. PubMed ID: 29455432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals.
    Hong H; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J
    Gut Liver; 2024 Jan; 18(1):147-155. PubMed ID: 37076993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.